MaaT Pharma

Our mission is to develop #microbiome-based therapies targeting mortality and comorbidities associated with cancer treatments.

[MaaT Pharma @MaaT_Pharma]

🔬 New insights into the biological activity of MaaT013

We are pleased to share a new collaborative publication in @FrontiersIn Microbiology exploring the biological activity of MaaT013 in acute Graft-versus-Host Disease (#aGvHD).
The study explores how MaaT013 may modulate key biological processes involved in aGvHD, providing exploratory insights into gut barrier integrity, Treg responses, microbial engraftment and immune homeostasis.

👉 Read the full article: https://t.co/kHSxzWAvkT

#MaaT013 #GvHD #Hematology #Microbiome #Microbiotherapy

[MaaT Pharma @MaaT_Pharma]

📰 [#CommuniquéDePresse] - MaaT Pharma annonce la tenue prochaine d’une réunion pré-IND avec la FDA et poursuit l’avancement de MaaT034 vers son développement clinique dans les tumeurs solides.

👉 Lire le communiqué de presse : https://t.co/0BEDmEflfX

[MaaT Pharma @MaaT_Pharma]

📰 [#PressRelease] - MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors

👉 Read more: https://t.co/VGFyTof6mN

[MaaT Pharma @MaaT_Pharma]

📰 [#CommuniquéDePresse] - MaaT Pharma fait le point sur le potentiel plan de développement de MaaT013 (Xervyteg®) suite à l’opinion négative du CHMP à l’issue de la procédure de réexamen.

👉 Lire le communiqué de presse : https://t.co/sTjjvH9pue

[MaaT Pharma @MaaT_Pharma]

📰 [#PressRelease] - MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination.

👉 Read more: https://t.co/VujwpPC2ur

[MaaT Pharma @MaaT_Pharma]

📰 [#CommuniquéDePresse] - MaaT Pharma annonce une tendance de vote négative du CHMP pour MaaT013 (Xervyteg®) dans le cadre du réexamen de sa demande d’autorisation de mise sur le marché conditionnelle en Europe.

👉 Lire le communiqué de presse : https://t.co/BeRDpo7MJR

[MaaT Pharma @MaaT_Pharma]

📰 [#PressRelease] - MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe.

👉 Read the full press release: https://t.co/m7ljYqBaEv

[MaaT Pharma @MaaT_Pharma]

🔬 𝗕𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗮 𝗖𝗲𝗻𝘁𝗲𝗿 𝗼𝗳 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 𝗳𝗼𝗿 𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗺𝗲-𝗯𝗮𝘀𝗲𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀
At MaaT Pharma, we combine scientific expertise, proprietary technologies and pharmaceutical-grade manufacturing to transform complex microbiome science into industrial microbiotherapies.

🦠 As a European Center of Excellence for microbiome drug development and manufacturing, we continuously invest in production capabilities, quality control and advanced characterization methods to support the development of next-generation microbiome therapeutics.

🔗 Learn more about our Development & Manufacturing Platform: https://t.co/veJ9MPjGSB

Take a look at some of our key achievements below ⬇️

#Microbiome #Biotech #Biomanufacturing #Innovation #LifeSciences #DrugDevelopment

[MaaT Pharma @MaaT_Pharma]

📸 Looking back on two inspiring days at #Excellentium Forum 2026, organized by @GlobalBRev at @EMLYON business school.

💡A highlight of the event was the panel discussion “From Breakthroughs to Better Lives: Leading for Impact across Health, Environment, and Society”, where Hervé Affagard joined Trine Bartholdy, Francisca Peixoto and Dana Vigier, under the moderation of Valérie Calenda.

The forum also offered valuable opportunities for exchange through the workshop sessions led by Guilhaume Debroas and Mathieu Fontaine. The conversations continued throughout the forum at the MaaT Pharma booth, where Michèle Boyer de Zordi had the pleasure of connecting with students, researchers, and industry professionals.

🙏 Thank you to everyone who joined these discussions and shared their perspectives. We greatly appreciated the opportunity to connect with so many talented students, researchers and professionals, and look forward to staying in touch.

@HAffagard
#Excellentium2026 #Biotech #Leadership #Healthcare #Microbiome #Innovation

[Know GvHD @know_gvhd]

Watch @Mohty_EBMT explain the risk of graft-versus-host disease (GvHD) after stem cell transplantation.

Watch here 👉 https://t.co/GovzJ4fr2b

This educational resource is independently supported by Therakos. All content is developed by SES in collaboration with an expert ambassador group. Funders are allowed no influence.

#KnowGvHD #GraftVersusHostDisease #GvHD #GvHDsm

[MaaT Pharma @MaaT_Pharma]

📢 [#Event] - We are excited to join the hashtag#Excellentium Forum 2026, on July 8–9 at @EMLYON business school in Lyon, France.

🎤 On July 8, Guilhaume Debroas, Ph.D. and Mathieu Fontaine will contribute to the afternoon workshop sessions (starting at 3:30 PM), sharing their perspectives on “From Research to Investment: Making Science Attractive to Investors” and engaging with the next generation of biotech leaders.

🎤 On July 9 (10:00–11:30 AM), Herve Affagard, MBA, Eng. will participate in the panel discussion: “From Breakthroughs to Better Lives: Leading for Impact across Health, Environment, and Society”.

🤝 Throughout the event, visit the MaaT Pharma booth and connect with Michèle BOYER de ZORDI to learn more about our mission to unlock the full potential of microbiome therapies for patients with cancer.

Looking forward to inspiring discussions, new connections, and advancing leadership across biotech and healthcare.

#Excellentium2026 #Biotech #Leadership #LifeSciences #Healthcare #Microbiome #Oncology #Innovation

[MaaT Pharma @MaaT_Pharma]

📢 𝗡𝗲𝘄 𝗶𝗻𝘀𝗶𝗴𝗵𝘁 𝗶𝗻𝘁𝗼 𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝘁𝗮-𝗱𝗿𝗶𝘃𝗲𝗻 𝗶𝗺𝗺𝘂𝗻𝗲 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻
A newly published study in Gut Microbes broadens our understanding of how commensal gut microbes contribute to immune tolerance and homeostasis. This study shows that F. duncaniae, A. muciniphila, B. obeum and R. intestinalis bacterial species induce tolerogenic DCs capable of priming naive CD4+ T cells into IL-10-producing DP8a regulatory T cells. DP8a Tregs are abundant in the colonic lamina propria and are emerging as key mediators of gut immune tolerance.

💡 This reinforces the mechanistic rationale for MaaT013 as a microbiome-based approach to amplify tolerogenic Tregs and potentially help control aGvHD.

👉 Read the full article here: https://t.co/QY6L5RFCwL

#Microbiome #aGvHD #Immunity #Microbiota #Health

[MaaT Pharma @MaaT_Pharma]

📢 #WorldMicrobiomeDay 2026 | Unlocking the potential of the microbiome, together.

At MaaT Pharma, advancing microbiome science to develop innovative therapeutic solutions is at the core of our mission. From research and clinical development to manufacturing and support teams, every colleague contributes to unlocking the potential of the microbiome to transform patient care.

On this World Microbiome Day, we are proud to stand together, united by a shared commitment to science, innovation, and patients 👇

#WorldMicrobiomeDay #WMD2026 #Microbiome #Innovation #Biotech

[MaaT Pharma @MaaT_Pharma]

📰[#CommuniquéDePresse] - MaaT Pharma annonce son intention de demander un réexamen du dossier à la suite de l’avis négatif du CHMP concernant MaaT013 dans le traitement de la maladie aiguë du greffon contre l’hôte

👉 Lire le communiqué de presse complet : https://t.co/I3NSfh7j54

[MaaT Pharma @MaaT_Pharma]

📰 [#PressRelease] - MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease

👉 Read the full press release here : https://t.co/cB5f4X3zWU

[MaaT Pharma @MaaT_Pharma]

🎥 [#AssembléeGénérale] - Le replay de notre Assemblée Générale du 16 juin 2026, ainsi que les documents associés, sont désormais disponibles sur notre site internet.

Nous vous invitons à consulter :
• La rediffusion complète de la séance,
• Les supports présentés,
• Les documents relatifs à l’AG.

👉 Retrouvez tous les éléments ici : https://t.co/EnLeCfj0y9

-----------------
🎥 [#AnnualGeneralMeeting] - The replay of our Annual General Meeting held on June 16, 2026, as well as the associated documents, are now available on our website.

We invite you to explore:
• The full session replay
• The presentation materials
• The AGM-related documents

👉 Find all the content here: https://t.co/dLSeQ1t9dw

[Shahram Kordasti @SKordasti]

One of the very interesting discussions today at #EHA2026 was about the role of the gut microbiome and FMT in patients undergoing HSCT, particularly in steroid-refractory acute GVHD.

The HERACLES study showed that pooled allogeneic FMT in GI aGVHD was associated with a GI response rate of around 38%, alongside increased microbial diversity and higher levels of butyrate-producing bacteria in responders.

In paediatric patients, data remain limited, but early experience suggests the procedure is feasible and relatively safe. More multicentre trials are clearly needed.

At the same time, the higher prevalence of MDR Enterobacterales in HSCT recipients, and its association with increased mortality, reminds us that microbiome restoration is not a peripheral issue.

The microbiome is becoming an important part of the future of transplant medicine.

#HSCT #GVHD #Microbiome #FMT #Haematology

[Shahram Kordasti @SKordasti]

Fascinating session at #EHA2026 on the role of the gut microbiome in response to cancer therapy.

Microbial modulation, including FMT, may help overcome resistance to immunotherapy, improve responses in treatment-naïve patients, and potentially reduce immune-related adverse events.

The key message: one size does not fit all. Donor selection, engraftment, pre-treatment protocols and disease context all matter.

The microbiome is becoming an important part of how we think about cancer immunotherapy. #EHA2026 #Microbiome #Immunotherapy

[MaaT Pharma @MaaT_Pharma]

[FR] - 🌍 En cette 𝗝𝗼𝘂𝗿𝗻𝗲́𝗲 𝗺𝗼𝗻𝗱𝗶𝗮𝗹𝗲 𝗱𝗲 𝗹’𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗻𝗲𝗺𝗲𝗻𝘁, MaaT Pharma est fière de partager son rapport RSE 2025 !

🎯 Une ambition claire : faire progresser la santé grâce au microbiote, en agissant concrètement pour l’environnement, nos collaborateurs et une gouvernance durable.
🔬 Innover en oncologie, tout en maîtrisant notre impact et en gardant les patients au centre : c’est l’engagement qui guide nos actions au quotidien.

👉 Découvrez notre rapport RSE 2025 ici : https://t.co/8oC14xxxX3

-----------
[EN] - 🌍 On this World Environment Day, MaaT Pharma is proud to share its 2025 CSR Report!
🎯 A clear ambition: advancing human health through the microbiome, while taking concrete action for the environment, our people, and sustainable governance.
🔬 Innovating in oncology while managing our impact and keeping patients at the center of everything we do—this is the commitment that guides our actions every day.

👉Discover our 2025 ESG report (French only): https://t.co/8oC14xxxX3

#WorldEnvironmentDay #Environment #RSE #CSR #Sustainability #Innovation #Health #ESG #Oncology